Travere Therapeutics stock saw a nearly 14% gain after being named a potential buyout candidate in 2026. Their drug Filspari, submitted for FDA approval to treat kidney disorder FSGS, could be a blockbuster. Cantor Fitzgerald believes the FDA may approve Filspari, signaling positive future prospects. While a buyout is possible, investing in Travere should hinge on the drug’s potential blockbuster status.

Before investing in Travere Therapeutics, note it wasn’t among the Motley Fool’s top 10 stock picks for high returns. The Stock Advisor has a history of market-crushing performance, so consider their recommendations for potential gains.

Read more at Nasdaq: Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday